The concept at the heart of the paper is deceptively simple. An antinomic medical term is one whose literal meaning or surface logic directly contradicts the true pathophysiology or clinical behavior of the condition it names. The authors, led by Etienne Rivière of the Internal Medicine and Infectious Diseases unit at Haut-Lévêque Hospital, catalog a series of such paradoxes and explore why they persist, why they matter, and what could be done about them. Their argument is not merely semantic. They contend that misleading nomenclature imposes a real cognitive load on trainees and practicing physicians alike, forcing the brain to memorize exceptions rather than understand mechanisms, at a time when medical knowledge is already expanding at an overwhelming pace.

The flagship example is the lupus anticoagulant, a name that manages to be wrong twice over. First, the test detects antibodies that are strongly associated with thrombosis, not bleeding; the “anticoagulant” label arises only because the antibodies interfere with clotting tests in the laboratory, prolonging the activated partial thromboplastin time, or aPTT, in a test tube. In the body, the opposite happens: patients carrying these antibodies face an elevated risk of venous and arterial clots. Second, despite the name, many people who test positive have no connection whatsoever to systemic lupus erythematosus. The result is a term that can confuse students preparing for exams and, more worryingly, clinicians making rapid decisions about thrombosis workups, where misreading the meaning of a prolonged aPTT in the presence of these antibodies can lead to inappropriate management.

The authors extend the analysis to the rheumatology clinic. So-called connective tissue diseases, a category that includes systemic lupus erythematosus and related systemic autoimmune conditions, are named for the tissue type once thought to be their unifying pathological substrate. Yet the clinical manifestations of these diseases—rashes, kidney inflammation, joint disease, blood count abnormalities—are driven by immune dysregulation that is not confined to connective tissue, and histological findings frequently fail to match the label. Similarly, lupus pernio, a chronic skin manifestation associated with sarcoidosis, has nothing to do with lupus erythematosus; the name borrows the Latin word for wolf because of the violaceous, wolf-like appearance of the lesions, a historical accident that continues to send learners down the wrong diagnostic path.

Gastroenterology supplies one of the most vivid examples: paradoxical diarrhea, also described in the literature as fecal impaction seepage. In elderly, immobile, or constipated patients, a hard mass of stool obstructs the rectum, and only liquid stool can leak around the blockage, producing what looks like diarrhea. The intuitive response—give an antidiarrheal agent—would be exactly wrong, potentially worsening the impaction and its complications. The correct treatment is disimpaction. The authors argue that the term itself, while memorable, encodes the paradox rather than resolving it, and that a name built on the underlying mechanism, such as overflow diarrhea secondary to fecal impaction, would teach the pathophysiology instead of merely flagging the surprise.

The paper also ventures into cardiology and infectious disease, where naming problems take subtler forms. Heart failure with preserved ejection fraction, or HFpEF, is defined partly by a preserved pumping measurement, yet the symptomatic reality for patients is diastolic dysfunction and congestion; the authors discuss how the framing around ejection fraction can obscure the hemodynamic mechanisms that actually produce breathlessness and fluid retention. In the aftermath of infections, a proliferating zoo of labels—post-acute infection syndromes, post-treatment Lyme disease syndrome, post-infectious chronic syndromes—describes overlapping clinical realities with inconsistent terminology, a fragmentation the authors see as an obstacle both to research and to patients seeking recognition of their persistent symptoms. They also cite heparin-induced thrombocytopenia, a condition in which the drop in platelet count is accompanied, paradoxically, by an increased risk of thrombosis driven by antibodies against platelet factor 4, so that the most feared complication of a platelet-lowering drug is clotting.

Why do such terms survive? The authors point to the deep historical layers of medical language. Many names were coined before the mechanisms were understood, when a visible feature, a laboratory artifact, or a superficial resemblance seemed like the most salient characteristic. Once embedded in textbooks, examination syllabi, billing codes, and decades of literature, a term acquires inertia that is difficult to overcome. Renaming is costly: it disrupts literature searches, breaks continuity with older studies, and requires international consensus in fields where even the definitions of the diseases themselves are contested. The result is a kind of linguistic path dependence, in which each generation of students must learn not only the biology but also the archaeology of the words.

The cost of this inertia, the authors argue, is measured in cognitive overload. Medical education has long been criticized for privileging encyclopedic memorization over mechanistic understanding, and antinomic terms are a concentrated expression of that problem. A student who learns that the lupus anticoagulant causes clots despite its name has memorized a fact; a student who learns why the name exists—because of an in vitro artifact in the aPTT assay—has acquired a transferable insight into laboratory medicine and antibody biology. The authors advocate a pedagogical shift away from rote learning of archaic labels and toward teaching the underlying mechanisms first, with the historical names presented explicitly as fossils of earlier misunderstanding rather than as neutral descriptors.

Beyond the classroom, the authors emphasize the consequences for patients. Terms like lupus anticoagulant or paradoxical diarrhea are not merely confusing to laypeople; they can be actively frightening or misleading when a patient reads them in a laboratory report or discharge summary. A person told they have an “anticoagulant” in their blood may reasonably wonder whether they are at risk of bleeding, when the actual clinical concern is thrombosis. The authors call for a global, cross-disciplinary effort to simplify medical language, involving clinicians, educators, linguists, and patient representatives, with the goal of fostering clinical competence and genuine comprehension rather than the accumulation of opaque vocabulary. They propose specific improvements to current nomenclature, suggesting that the most misleading terms be critically re-examined and, where feasible, renamed in ways that reflect mechanism rather than historical accident.

The paper, published as an open-access debate article, is unlikely to settle the question on its own—renaming entrenched medical terms is a slow, collective enterprise—but it crystallizes a problem that many educators recognize and rarely name so directly. In an era when artificial intelligence tools can retrieve facts instantly, the authors suggest, the value of medical education lies increasingly in deep mechanistic reasoning, and language that contradicts mechanism is a tax on that reasoning. Whether the community chooses to reform its most paradoxical terms or simply to teach them more honestly, the underlying message stands: in medicine, the name of a disease should illuminate the disease, not conceal it, and every term that belies the biology it describes is a small, persistent obstacle between knowledge and understanding.

Subject of Research: Misleading antinomic terminology in medical nomenclature and its impact on clinical reasoning and medical education

Article Title: Medical antinomy: when the name belies the disease

Article References: Rivière, E., Mathé, A., Rivière, P., Bonnet, G., James, C., & Guy, A. (2026). Medical antinomy: when the name belies the disease. BMC Medicine. https://doi.org/10.1186/s12916-026-05220-0

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05220-0

Keywords: medical education, nomenclature, lupus anticoagulant, connective tissue diseases, paradoxical diarrhea, heparin-induced thrombocytopenia, post-acute infection syndromes, clinical reasoning, cognitive overload, systemic lupus erythematosus, BMC Medicine, medical language

The numbers behind the argument are striking. Antiphospholipid syndrome, the archetypal autoimmune clotting disorder, affects roughly 40 to 50 per 100,000 people in western populations, with a four-to-one female predominance, and carries an annual incidence of one to two cases per 100,000. Around 20 to 30 percent of patients with systemic lupus erythematosus carry antiphospholipid antibodies, and about 40 percent of those go on to develop secondary antiphospholipid syndrome. Patients who have both lupus and antiphospholipid antibodies face significantly higher risks of clotting and of recurrence than either condition alone. Rheumatoid arthritis, giant cell arteritis, Takayasu’s arteritis, polyarteritis nodosa and ANCA-associated vasculitis all add to the burden, as do immune-driven syndromes such as heparin-induced thrombocytopenia and the vaccine-induced clotting disorder VITT that emerged during the COVID-19 pandemic.

What makes these conditions clinically treacherous is that, unlike inherited clotting tendencies, they can strike any part of the circulation. In antiphospholipid syndrome, venous thromboembolism accounts for 39 percent of first events, but stroke follows at nearly 20 percent, with transient ischaemic attacks and heart attacks behind it. Clots also form in unusual places: the cerebral venous sinuses, the splanchnic veins, even the retina. In a five-year international cohort, the single most frequent recurrent event was stroke, a sobering signal that standard anticoagulation incompletely protects these patients. Microvascular thrombosis and pregnancy complications complete a picture that disproportionately afflicts younger adults, especially women, precisely the people conventional cardiovascular screening tends to overlook.

At the mechanistic heart of the problem lies immunothrombosis, the ancient host-defence programme that uses clot formation to wall off circulating pathogens. When autoantibodies hijack this machinery, the result is pathological thrombo-inflammation. The best-characterised culprit is the family of antiphospholipid antibodies, particularly those directed against beta-2 glycoprotein I. These antibodies bind phospholipid-binding proteins on endothelial cells, monocytes and platelets, triggering tissue factor expression, thrombin generation and platelet aggregation, and creating a sustained hypercoagulable state that spans arteries, veins and the microcirculation.

Platelets themselves turn out to be immune sentinels, and the review places the platelet Fc gamma receptor IIa at the centre of the story. This receptor, the only Fc receptor on platelets, binds the tail of IgG immune complexes. When pathogenic antibodies cross-link it, a signalling cascade through Src family kinases, Syk and phospholipase C gamma 2 rapidly activates the platelet, spurring granule release, integrin activation and aggregation. Activated platelets shed phosphatidylserine-rich microparticles that serve as catalytic surfaces for thrombin generation and express P-selectin, recruiting neutrophils and monocytes. In antiphospholipid syndrome, heparin-induced thrombocytopenia and VITT alike, Fc gamma receptor IIa signalling is the common final pathway converting adaptive immune mischief into arterial thrombosis, a fact already exploited therapeutically through high-dose intravenous immunoglobulin.

Neutrophils add a second layer of amplification. Activated neutrophils cast out neutrophil extracellular traps, web-like lattices of DNA, histones and granular enzymes that normally ensnare microbes but in autoimmunity provide scaffolds for fibrin deposition, activate platelets and injure the endothelium. In lupus and antiphospholipid syndrome, impaired clearance of these traps sustains vascular inflammation. Meanwhile complement fragments C3a and C5a stoke cytokine release and thrombin generation, while the membrane attack complex punches holes in endothelial cells; experimental work shows complement activation is essential to clotting in antiphospholipid syndrome, making complement inhibition a promising strategy for severe disease.

The endothelium itself is transformed from a guardian into an accomplice. Healthy vessels secrete nitric oxide and prostacyclin and display anticoagulant proteins, but inflammatory cytokines such as tumour necrosis factor-alpha, interleukin-1 and interferon-alpha flip the switch: adhesion molecules appear, von Willebrand factor floods out, natural anticoagulants are downregulated, and plasminogen activator inhibitor-1 throttles fibrinolysis. Oxidative stress strips away nitric oxide bioavailability. In lupus and rheumatoid arthritis this same endothelial dysfunction accelerates atherosclerosis, so patients develop premature arterial disease years or decades ahead of schedule. Traditional risk factors then multiply the damage: smoking boosts autoantibody production, obesity feeds chronic low-grade inflammation, and long-term glucocorticoid therapy worsens blood pressure, lipids and insulin resistance.

Paradoxically, several of these conditions cause clotting despite depleting platelets. In immune thrombocytopenia, antibodies against platelet glycoproteins drive the count down, yet patients still clot more often, through microparticle formation, enhanced thrombin generation and endothelial dysfunction. In autoimmune haemolytic anaemia, antibodies destroy red cells, and the liberated iron, procoagulant microparticles, complement activation and nitric oxide depletion together conspire toward thrombosis. Even antibodies against the natural anticoagulants protein C and protein S have been described, producing catastrophic syndromes such as purpura fulminans and symmetrical peripheral gangrene. The lesson, the authors stress, is that thrombosis in strange contexts or without traditional risk factors should prompt a search for an immune cause.

Diagnosis and risk stratification remain stubbornly difficult because conventional tools are calibrated to ordinary populations. Framingham and SCORE2 scores systematically underestimate vascular risk in inflammatory disease, which is why several rheumatology societies recommend adjustment factors. Laboratory assessment centres on antiphospholipid antibody testing, where persistence on repeat testing after at least twelve weeks confirms clinical significance, and so-called triple positivity marks particularly high recurrence risk. Anticoagulation strategy is similarly nuanced: vitamin K antagonists remain the standard for thrombotic antiphospholipid syndrome because randomised trials showed rivaroxaban and other direct oral anticoagulants carry unacceptably high arterial recurrence rates in triple-positive patients, though carefully selected low-risk patients intolerant of warfarin may still qualify. Hydroxychloroquine, with its platelet-calming and endothelial-protecting effects, statins, aggressive inflammation control and rigorous management of blood pressure, lipids and glucose all form part of the preventive package, alongside minimising cumulative steroid exposure.

The review closes with a policy prescription that amounts to a cultural shift. The authors call for European health systems to designate autoimmune diseases as cardiovascular risk-enhancing conditions, embedding cardiovascular prevention within routine rheumatology and haematology care rather than leaving it to cardiology alone. Multidisciplinary pathways linking primary care, rheumatology, haematology, cardiology and obstetrics, supported by harmonised registries and autoimmune-specific risk prediction tools, would allow earlier detection of high-risk patients through blood pressure, lipid and glucose monitoring, vascular imaging and structured screening of carriers of antiphospholipid antibodies. The economic stakes are substantial: venous thromboembolism costs the United States an estimated seven to ten billion dollars annually, and stroke cost 32 European countries roughly 31 billion euros in 2017, with the autoimmune contribution disproportionately large because patients are young and comorbidities multiply. Emerging therapies, from CD19-directed CAR-T cells to bispecific antibodies that deplete the plasma cells making pathogenic antibodies, hint that in the future the source of the problem, not just its downstream clot, might finally be silenced.

Subject of Research: Mechanisms, epidemiology and prevention of autoimmune-associated thrombosis

Article Title: Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies

Article References: Arachchillage, D. J., Preece, M. V., & Laffan, M. (2026). Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies. The Lancet Regional Health – Europe, 70, Article 101850. https://doi.org/10.1016/j.lanepe.2026.101850

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101850

Keywords: autoimmune disease, thrombosis, antiphospholipid syndrome, systemic lupus erythematosus, immunothrombosis, endothelial dysfunction, neutrophil extracellular traps, complement activation, VITT, heparin-induced thrombocytopenia, cardiovascular risk, anticoagulation